{"questions": [{"id": "6402c910201352f04a00000c", "type": "yesno", "body": "Can losartan reduce brain atrophy in Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34687634", "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "http://www.ncbi.nlm.nih.gov/pubmed/20620665"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease.", "offsetInBeginSection": 2590, "offsetInEndSection": 2740, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "text": "CONCLUSION\nThis study will identify whether losartan is efficacious in the treatment of AD and whether definitive Phase III trials are warranted.", "offsetInBeginSection": 1846, "offsetInEndSection": 1996, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "Treatment trials in AD should consider the effects of normal aging; adjusting for baseline characteristics can significantly reduce required sample sizes.", "offsetInBeginSection": 142, "offsetInEndSection": 292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "text": "Medial temporal sparing in non-amnestic Alzheimer's disease may thus be due in part to later onset of medial temporal degeneration than in amnestic patients rather than different rates of atrophy over time.", "offsetInBeginSection": 2293, "offsetInEndSection": 2449, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "text": "METHODS AND FINDINGS\nSingle-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B(6) and B(12) in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment.", "offsetInBeginSection": 1933, "offsetInEndSection": 2083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "Treatment trials in AD should consider the effects of normal aging; adjusting for baseline characteristics can significantly reduce required sample sizes.", "offsetInBeginSection": 1248, "offsetInEndSection": 1398, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640f857d201352f04a00002b", "type": "factoid", "body": "What is CHARMS with respect to medical review of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31762119", "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "http://www.ncbi.nlm.nih.gov/pubmed/36149932"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "text": "However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "text": "Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.", "offsetInBeginSection": 690, "offsetInEndSection": 840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "text": "We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc).", "offsetInBeginSection": 405, "offsetInEndSection": 555, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.", "offsetInBeginSection": 389, "offsetInEndSection": 539, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "text": "We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of bias assessment.", "offsetInBeginSection": 864, "offsetInEndSection": 1014, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "text": "As the economic evaluations differed in method and perspective among the studies, the results could not be generalized.", "offsetInBeginSection": 960, "offsetInEndSection": 1110, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "text": "A checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.", "offsetInBeginSection": 517, "offsetInEndSection": 667, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36149932", "text": "Two authors independently assessed studies for inclusion and undertook data extraction following recommendations of the CHARMS checklist, while quality assessment was performed using the PROBAST tool.", "offsetInBeginSection": 1027, "offsetInEndSection": 1177, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eb95201352f04a00002e", "type": "list", "body": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36375644", "http://www.ncbi.nlm.nih.gov/pubmed/35191471"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36375644", "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.", "offsetInBeginSection": 1271, "offsetInEndSection": 1421, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35191471", "text": "Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachycardia (VT) in hPLN-R14del relative to hPLN-WT.", "offsetInBeginSection": 914, "offsetInEndSection": 1064, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64162fb0690f196b5100001a", "type": "list", "body": "What are the most common mutation types in Duchenne muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33741226", "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "http://www.ncbi.nlm.nih.gov/pubmed/33039804"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "text": "About 33% of all patients are due to de novo mutations and germ line mosaicism is frequently observed.", "offsetInBeginSection": 115, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "text": "in children and is clinically characterized by progressive muscle degeneration and severe cardiomyopathy. In this study, renal epithelial cells were o", "offsetInBeginSection": 134, "offsetInEndSection": 284, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef3ebf36125a42600000a", "type": "factoid", "body": "What is the target of Litifilimab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36069871", "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "http://www.ncbi.nlm.nih.gov/pubmed/36069871"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "4, 8, 12, 16, and 20, with the primary end point of evaluating cutaneous lupus activity. The trial design was subsequently modified; adults with SLE, ", "offsetInBeginSection": 686, "offsetInEndSection": 836, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "(Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.", "offsetInBeginSection": 2523, "offsetInEndSection": 2673, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "text": "Assuming that the T lymphocyte is the target site for CS, local therapy reaches only a small fraction of the T cell population.", "offsetInBeginSection": 997, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "text": "Thus, recent data suggest that avoiding hyperpyrexia, rather than cooling \"per se,\" may be considered the main therapeutic target to avoid secondary brain damage after out-of-hospital cardiac arrest.", "offsetInBeginSection": 487, "offsetInEndSection": 637, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "(Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.", "offsetInBeginSection": 2468, "offsetInEndSection": 2618, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136fbf201352f04a00003d", "type": "factoid", "body": "What is AUROC in context of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35879562", "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "http://www.ncbi.nlm.nih.gov/pubmed/34154565", "http://www.ncbi.nlm.nih.gov/pubmed/35505048", "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "http://www.ncbi.nlm.nih.gov/pubmed/31093546"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "text": "The predictive accuracy of an individual biomarker on cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included.", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "text": "RESULTS\nFor logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks.", "offsetInBeginSection": 1005, "offsetInEndSection": 1155, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "text": "Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.", "offsetInBeginSection": 1325, "offsetInEndSection": 1475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "text": "Model performance was assessed using area under the receiver operator characteristic curve (AUROC).", "offsetInBeginSection": 598, "offsetInEndSection": 748, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34154565", "text": "Predictive performance and optimal diagnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC).", "offsetInBeginSection": 536, "offsetInEndSection": 686, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35505048", "text": "The predictive performance of conventional scoring models and machine learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC).", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "text": "Models not relevant to spinal procedures were excluded.", "offsetInBeginSection": 471, "offsetInEndSection": 621, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "text": "Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.", "offsetInBeginSection": 837, "offsetInEndSection": 987, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "text": "Deep learning models achieved high accuracy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90).", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "text": "Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performance ability.", "offsetInBeginSection": 112, "offsetInEndSection": 262, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa13da201352f04a000001", "type": "yesno", "body": "Is PRP-40 regulation of microexons a conserved phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33621242", "http://www.ncbi.nlm.nih.gov/pubmed/34348142"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "text": "Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserved and play critical roles in promoting neuronal differentiation and development.", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e15690f196b51000020", "type": "yesno", "body": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "http://www.ncbi.nlm.nih.gov/pubmed/30544588"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "Primary myoblasts isolated from mdx mice were challenged with an inflammatory stimulus and treated with fenofibrate.", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "Duchenne muscular dystrophy is a lethal neuromuscular disease that currently has no effective therapy.", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "In addition, we showed that Duchenne muscular dystrophy patient myocardium exhibited increased TRPC6, m-calpain, and calpain cleavage products compared with control human myocardium.", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "Duchenne muscular dystrophy is known to be caused by a defective gene of dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable.", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "DISCUSSION\nCasimersen was well tolerated in participants with DMD amenable to exon 45 skipping.", "offsetInBeginSection": 1417, "offsetInEndSection": 1567, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "Our primary study objective was to evaluate safety and tolerability of casimersen; the secondary objective was to characterize the plasma pharmacokinetics.", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "Currently, there is no effective therapy for this disorder.", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02ceaf36125a426000015", "type": "summary", "body": "Which are the targets of Tirzepatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35210595", "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "http://www.ncbi.nlm.nih.gov/pubmed/32730231"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "text": "Its association with cardiovascular outcomes requires evaluation.", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "text": "The development of high-dose GLP-1 RAs and the dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide resulted in increasing numbers of people reaching HbA1c and body weight targets, with up to 62% attaining normoglycaemia with 15-mg tirzepatide.", "offsetInBeginSection": 1479, "offsetInEndSection": 1629, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "text": "This first-in-class agent serves as a coagonist for both the GLP-1 and GIP receptors.", "offsetInBeginSection": 897, "offsetInEndSection": 1047, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "The secondary outcomes were to compare tirzepatide (5 mg, 10 mg, and 15 mg) versus insulin degludec for the proportion and duration of time in tight target range at 24 and 52 weeks.", "offsetInBeginSection": 1783, "offsetInEndSection": 1933, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "text": "Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis.", "offsetInBeginSection": 819, "offsetInEndSection": 969, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "text": "BACKGROUND AND OBJECTIVE\nTirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is approved in the US as a treatment for type 2 diabetes and is under development for long-term weight management, heart failure with preserved ejection fraction, and nonalcoholic steatohepatitis.", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "text": "Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.", "offsetInBeginSection": 2516, "offsetInEndSection": 2666, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "text": "Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes.", "offsetInBeginSection": 24, "offsetInEndSection": 174, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin.", "offsetInBeginSection": 3278, "offsetInEndSection": 3428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "text": "Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.", "offsetInBeginSection": 66, "offsetInEndSection": 216, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640e2616201352f04a00002a", "type": "yesno", "body": "Is medical hydrology the same as Spa therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12110784"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110784", "text": "Within conservative approaches, spa hydrotherapy is popular among patients with venous disorders in Europe, but whether the practice is associated with health or social benefits remains controversial.", "offsetInBeginSection": 159, "offsetInEndSection": 309, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410fa66201352f04a000034", "type": "summary", "body": "How does CYP1A2 relate to coffee consumption and apetite?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18157525", "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "http://www.ncbi.nlm.nih.gov/pubmed/18157525"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "CONCLUSIONS\nHabitual heavy coffee consumption increases CYP1A2 activity.", "offsetInBeginSection": 1326, "offsetInEndSection": 1476, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "text": "CYP1A2 plays a key role in the metabolism of both estrogen and coffee.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "Controlling for the effect of smoking, heavy coffee consumption habit and oral contraceptive use, significantly lower 17X/137X ratio was observed in Serbs than in Swedes (P=0.0003).", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e73690f196b51000023", "type": "yesno", "body": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32691988", "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "http://www.ncbi.nlm.nih.gov/pubmed/26573217"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "text": "In this year's neuromuscular Year in Review, we focus on Duchenne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effect of eteplirsen, the cardiopulmonary effects of ataluren, and a study comparing the use of spironolactone with eplerenone for the treatment of DMD-related cardiomyopathy.", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "INTERPRETATION\nOver 3 years of follow-up, eteplirsen-treated patients showed a slower rate of decline in ambulation assessed by 6MWT compared to untreated matched HC.", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "text": "We review the development of exon 51 skipping therapy with eteplirsen for Duchenne muscular dystrophy, including the recent report of long-term, sustained dystrophin production.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": "Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial.", "offsetInBeginSection": 551, "offsetInEndSection": 701, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "text": "However, the limited efficacy of eteplirsen underscores the importance to improve systemic delivery and efficacy.", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": "Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial.", "offsetInBeginSection": 578, "offsetInEndSection": 728, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "Most frequent treatment-related adverse events were headache and vomiting; none led to treatment discontinuation.ConclusionsThis large, multicenter study contributes to the growing body of evidence for eteplirsen, confirming a positive treatment effect, favorable safety profile, and slowing of disease progression versus natural history.", "offsetInBeginSection": 1692, "offsetInEndSection": 1842, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "OBJECTIVE\nTo continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03939f36125a42600001b", "type": "summary", "body": "What is the use of darolutamide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33135506", "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "http://www.ncbi.nlm.nih.gov/pubmed/32905676", "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "http://www.ncbi.nlm.nih.gov/pubmed/32073798", "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "http://www.ncbi.nlm.nih.gov/pubmed/35179323"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33135506", "text": "Introduction: Currently, in prostate cancer, an increasing number of novel drugs are being used to delay its advancement to metastatic castration-resistant prostate cancer (mCRPC).", "offsetInBeginSection": 183, "offsetInEndSection": 333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "text": "BACKGROUND\nDarolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer.", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "text": "amide 600\u00a0mg twice daily or matched placebo while continuing androgen deprivation therapy. The primary endpoint was MFS.\n\n\nRESULTS\nIn Japan, 95 patien", "offsetInBeginSection": 526, "offsetInEndSection": 676, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "text": "CONCLUSIONS\nDarolutamide 600 mg twice daily demonstrates predictable linear pharmacokinetics and sustainably high plasma concentrations, suggesting the potential for constant inhibition of the androgen receptor signaling pathway.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "text": "Local symptom control was assessed by first prostate cancer-related invasive procedures and post hoc analyses of time to deterioration in quality of life (QoL) using total urinary and bowel symptoms, and individual questions for these symptoms from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module subscales and Functional Assessment of Cancer Therapy-Prostate prostate cancer subscale.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32905676", "text": "The data for the analysis of overall survival were immature at the time of the primary analysis.", "offsetInBeginSection": 61, "offsetInEndSection": 211, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "INTRODUCTION\nApalutamide and darolutamide are next-generation androgen receptor inhibitors that have demonstrated superior efficacy compared to placebo in men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32073798", "text": "The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo.", "offsetInBeginSection": 55, "offsetInEndSection": 205, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "shed data from the ARAMIS study (darolutamide\u00a0+\u00a0ADT) for clinically relevant baseline measures. Hazard ratios (HR) and 95% credible intervals (CrI) we", "offsetInBeginSection": 620, "offsetInEndSection": 770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136664201352f04a00003b", "type": "list", "body": "What are the main clinical features of small-fiber neuropathy (SFN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17868250", "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "http://www.ncbi.nlm.nih.gov/pubmed/31943276", "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "http://www.ncbi.nlm.nih.gov/pubmed/23982054"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "text": "Small-fiber neuropathy (SFN) is diagnosed on the basis of clinical features and specialized tests of small-fiber function because standard nerve conduction studies are normal.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "text": "The main clinical features include neuropathic pain and autonomic disturbance, which are occasionally disclaimed due to outstanding fatigue, daily performance decline, anxiety, and depression.", "offsetInBeginSection": 288, "offsetInEndSection": 438, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "text": "Among others, these tests include assessment of epidermal nerve fiber density, temperature sensation tests for sensory fibers and sudomotor and cardiovagal testing (QSART) for autonomic fibers.", "offsetInBeginSection": 340, "offsetInEndSection": 490, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "text": "METHODS\nThis is a retrospective, observational study of sequential patients diagnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November 2016 to the middle of July 2019 at the Cantonal Hospital Lucerne, central Switzerland.", "offsetInBeginSection": 341, "offsetInEndSection": 491, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31943276", "text": "In recent years, several disorders have unexpectedly been reported in association with SFN, on clinical grounds and complementary investigations, including quantitative sensory testing, intraepidermal nerve fiber density and confocal corneal microscopy.", "offsetInBeginSection": 364, "offsetInEndSection": 514, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "text": "No differences of electrophysiological parameters existed between IENFD abnormal and normal groups.", "offsetInBeginSection": 18, "offsetInEndSection": 168, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "text": "Skin punch biopsy may also be repeated for surveillance of the disease as well as measuring response to treatments.", "offsetInBeginSection": 170, "offsetInEndSection": 320, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "text": "Small fiber neuropathy (SFN) is characterized by negative sensory symptoms (thermal and pinprick hypoesthesia) reflecting peripheral deafferentation and positive sensory symptoms and signs (burning pain, allodynia, hyperalgesia), which often dominate the clinical picture.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "text": "Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy.", "offsetInBeginSection": 322, "offsetInEndSection": 472, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "text": "SFN was defined by the presence of suggestive sensory painful symptoms with normal nerve conduction studies and abnormal neurophysiologic tests for small nerve fibers or a low intraepidermal nerve fiber density at skin biopsy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c53e690f196b51000012", "type": "factoid", "body": "When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24573551", "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "http://www.ncbi.nlm.nih.gov/pubmed/27821604"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "text": "as granted on the basis of the high ORRs and durable responses. On November 20, 2013, crizotinib received full approval based on an improvement in pro", "offsetInBeginSection": 1086, "offsetInEndSection": 1236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "text": "It was additionally approved for patients with metastatic non-small cell lung cancer by the FDA in October, 2015.", "offsetInBeginSection": 547, "offsetInEndSection": 697, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "text": "andomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with met", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "text": "In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6417949d690f196b51000035", "type": "list", "body": "Which gene therapies are under investigation for Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30119719", "http://www.ncbi.nlm.nih.gov/pubmed/32542436", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "http://www.ncbi.nlm.nih.gov/pubmed/27594988"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "text": "Such translational research has led to the approval of two genetic therapies by the US Food and Drug Administration: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular atrophy, which are both antisense oligonucleotides that modify pre-mRNA splicing.", "offsetInBeginSection": 420, "offsetInEndSection": 570, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32542436", "text": "Molecular therapies such as direct gene transfer or alternative processing of the disease-specific gene play an important role in this transformation.In particular, the course of 5q-associated spinal muscle atrophy has changed significantly due to the availability of such causal therapies, while the results of ongoing studies are still pending for most muscle diseases.", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "In the present review, we describe current methods of induced pluripotent stem cell generation and discuss their implications for the study, modeling, and development of cell-based therapies for Duchenne muscular dystrophy.", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "text": "A number of the viral vector systems, myoblast transfer, and direct injection techniques that are currently under investigation for the treatment of neuromuscular disorders are reviewed here.", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "text": "Other mechanisms include muscle regeneration, antioxidants, and antifibrosis and anti-inflammatory pathways.", "offsetInBeginSection": 749, "offsetInEndSection": 899, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "text": "e for the primary defect of this disease. These include dystrophin gene-replacement strategies, genetic modification techniques to restore dystrophin ", "offsetInBeginSection": 1307, "offsetInEndSection": 1457, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "text": "Gene mapping has been applied successfully in carrier detection and antenatal diagnosis, and specific gene probes will soon become available for carrier testing for the two most common forms of muscular dystrophy, Duchenne muscular dystrophy and myotonic dystrophy.", "offsetInBeginSection": 741, "offsetInEndSection": 891, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "text": "gned to repair the primary genetic defect, called 'exon skipping' and 'nonsense codon suppression'.\n\n\nRECENT FINDINGS\nA drug, PTC124, was identified t", "offsetInBeginSection": 193, "offsetInEndSection": 343, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "text": "oper care to patients according to published guidelines. With mutation-specific therapies under development for DMD, a correct diagnosis is now also i", "offsetInBeginSection": 296, "offsetInEndSection": 446, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "text": "In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.", "offsetInBeginSection": 478, "offsetInEndSection": 628, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02a82f36125a426000013", "type": "yesno", "body": "Does CIDEB mutation protect from liver disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34646017", "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "http://www.ncbi.nlm.nih.gov/pubmed/35939579"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34646017", "text": "CIDEB, which regulates lipid droplet metabolism in hepatocytes17-19, and GPAM, which produces storage triacylglycerol from free fatty acids20,21, also had a significant excess of mutations.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "We also found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect.", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "CONCLUSIONS\nRare germline mutations in CIDEB conferred substantial protection from liver disease.", "offsetInBeginSection": 2112, "offsetInEndSection": 2262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "We also found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect.", "offsetInBeginSection": 942, "offsetInEndSection": 1092, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089b21201352f04a000021", "type": "summary", "body": "Can you summarize the function of CDK9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20930849", "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "http://www.ncbi.nlm.nih.gov/pubmed/34146121", "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "http://www.ncbi.nlm.nih.gov/pubmed/21143121"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20930849", "text": "er, CDK9 also forms a complex with cyclin K, the function of which is less clear. Using a synthetic lethal RNA interference screen in human cells, we ", "offsetInBeginSection": 205, "offsetInEndSection": 355, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "text": "Although cyclin\u2011dependent kinase 9 (CDK9) has a definitive pathogenic role in various types of cancer, little is known concerning its function in endometrial cancer.", "offsetInBeginSection": 155, "offsetInEndSection": 305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "text": "CDK9 also binds to cyclin K but the function of this CDK9-cyclin K complex is less clear.", "offsetInBeginSection": 302, "offsetInEndSection": 452, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146121", "text": "Here, I provide an overview of CDK9 function and regulation, with an emphasis on CDK9 dysregulation in human diseases.", "offsetInBeginSection": 810, "offsetInEndSection": 960, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "text": "Although cyclin-dependent kinase (CDK) 9 has an established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined.", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "text": "The CDK9 inhibitory activity of the derivatives was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC(50) < 100 nM) was determined.", "offsetInBeginSection": 700, "offsetInEndSection": 850, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eead201352f04a000030", "type": "summary", "body": "How does RBM24 control QT interval?", "documents": [], "snippets": []}, {"id": "64105502201352f04a00002d", "type": "yesno", "body": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23909763", "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "http://www.ncbi.nlm.nih.gov/pubmed/28648683"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23909763", "text": "However, in Duchenne muscular dystrophy (DMD), identifying changes in function is not straightforward.", "offsetInBeginSection": 184, "offsetInEndSection": 334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "text": "CONCLUSIONS\nOur study indicates that the North Star Ambulatory Assessment is practical and reliable.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "text": "INTRODUCTION\nThere is a need for reliable and properly validated outcome measures in Duchenne muscular dystrophy, both to monitor functional impairment and to assess the impact of new therapies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "text": "CONCLUSION\nThe results from the study suggest that video NSAA is partially feasible and reliable.", "offsetInBeginSection": 1115, "offsetInEndSection": 1265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "text": "These results provide useful information for the assessment and counselling of young DMD boys and for the design of clinical trials in this age group.", "offsetInBeginSection": 381, "offsetInEndSection": 531, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "text": "The scores on the North Star assessment ranged from 6/34 to 34/34.", "offsetInBeginSection": 723, "offsetInEndSection": 873, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "text": "North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional capacity in boys with Duchenne muscular dystrophy.", "offsetInBeginSection": 1382, "offsetInEndSection": 1532, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f032caf36125a42600001a", "type": "summary", "body": "What is the mechanism of action of rilzabrutinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35417637", "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "http://www.ncbi.nlm.nih.gov/pubmed/33942286"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "BACKGROUND\nRilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fc\u03b3 receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "These data suggest that BTK inhibition may be a promising treatment strategy and support further investigation of rilzabrutinib for the treatment of pemphigus.", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "We examined the pharmacodynamic profile of rilzabrutinib and its preclinical mechanisms of action.", "offsetInBeginSection": 344, "offsetInEndSection": 494, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "In conclusion, rilzabrutinib, even at supratherapeutic doses, had no clinically relevant effects on ECG parameters, including the QTc interval.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "CONCLUSIONS\nRilzabrutinib was active and associated with only low-level toxic effects at all dose levels.", "offsetInBeginSection": 1877, "offsetInEndSection": 2027, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "Rilzabrutinib is characterized by reversible covalent BTK binding, long BTK residence time with low systemic exposure, and multiple mechanistic and biological effects on immune cells.", "offsetInBeginSection": 1465, "offsetInEndSection": 1615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "Primary objectives: part A - pharmacokinetics (PK) of rilzabrutinib \u00b1 ritonavir, safety, and optimal dose for Part B; Part B - effect of rilzabrutinib therapeutic and supratherapeutic concentration on electrocardiogram (ECG) parameters.", "offsetInBeginSection": 660, "offsetInEndSection": 810, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": "Remibrutinib being more potent and showing a better profile of inhibition of Btk-dependent platelet activation vs. hemostatic impairment than rilzabrutinib may be considered for further development as an antiplatelet drug.", "offsetInBeginSection": 1650, "offsetInEndSection": 1800, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "CONCLUSIONS\nRilzabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris.", "offsetInBeginSection": 1666, "offsetInEndSection": 1816, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641368ee201352f04a00003c", "type": "list", "body": "What are the  types/categories of adult diffuse gliomas.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34729052", "http://www.ncbi.nlm.nih.gov/pubmed/36299937", "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "http://www.ncbi.nlm.nih.gov/pubmed/35562130", "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "http://www.ncbi.nlm.nih.gov/pubmed/35578106"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": "The objectives of the current study were to assess the frequency of IDH mutation, ATRX expression loss, p53 overexpression, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopathological features.", "offsetInBeginSection": 609, "offsetInEndSection": 759, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299937", "text": "In the new WHO classification 2021, adult-type diffuse astrocytic gliomas subdivide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma.", "offsetInBeginSection": 198, "offsetInEndSection": 348, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "text": "The 2021 World Health Organization (WHO) classifies gliomas as adult-type diffuse gliomas or circumscribed astrocytic gliomas depending on their histology and molecular features.", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35562130", "text": "Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype.", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "text": "One of the most significant of these changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the main-line diagnosis, although a great deal of heterogeneity in the clinical outcome still remains to be explained within these categories.", "offsetInBeginSection": 494, "offsetInEndSection": 644, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "text": "Adult diffuse gliomas form a heterogeneous group of tumors of the central nervous system that vary greatly in histology and prognosis.", "offsetInBeginSection": 38, "offsetInEndSection": 188, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "text": "In the 5th edition of WHO classification of central nervous system tumors published in the end of 2021, one of the most important revisions is the division of the classification into adult-type and pediatric-type diffuse gliomas, and the latter is further divided into pediatric-type diffuse low-grade gliomas and pediatric-type diffuse high-grade gliomas.", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "text": "The benefits and utility of methylation-based classification in diffuse gliomas demonstrated to date are described.", "offsetInBeginSection": 292, "offsetInEndSection": 442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": " which could be useful for the evaluation of prognosis, especially Grade III and II. Although the immunohistochemical approach does not replace geneti", "offsetInBeginSection": 1595, "offsetInEndSection": 1745, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "text": "Many tumors have also been reconceptualized into new \"supercategories,\" including adult-type diffuse gliomas, pediatric-type diffuse low- and high-grade gliomas, and circumscribed astrocytic gliomas.", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415ca99690f196b51000019", "type": "yesno", "body": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33792221", "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "http://www.ncbi.nlm.nih.gov/pubmed/33689570", "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "http://www.ncbi.nlm.nih.gov/pubmed/29499327"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33792221", "text": " are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates ac", "offsetInBeginSection": 525, "offsetInEndSection": 675, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "text": "To date, CAR T cell activity has been even more limited in solid malignancies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33689570", "text": "Chimeric antigen\u00a0receptor (CAR) T-cell therapy is a revolutionary addition to the burgeoning field of immunotherapy.", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "text": "This Review will characterize challenges with current CAR T designs for hematologic malignancies and solid tumors and emphasize preclinical and clinical strategies to overcome them with novel CAR T cell therapies.", "offsetInBeginSection": 85, "offsetInEndSection": 235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "text": "Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA).", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "text": "Two commercial chimeric antigen receptor (CAR) T cell therapies for CD19-expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration.", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e4b690f196b51000022", "type": "yesno", "body": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "http://www.ncbi.nlm.nih.gov/pubmed/30544588"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "sured by Western blot and immunohistochemistry.\n\n\nCONCLUSION\nGolodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed in", "offsetInBeginSection": 1501, "offsetInEndSection": 1651, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "Duchenne muscular dystrophy is a lethal neuromuscular disease that currently has no effective therapy.", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "Duchenne muscular dystrophy is known to be caused by a defective gene of dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable.", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "text": "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "CLASSIFICATION OF EVIDENCE\nThis study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.", "offsetInBeginSection": 1798, "offsetInEndSection": 1948, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "rsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.\n\n\nMETHODS\nPart 1 was a randomized, double-blind, placebo-co", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "Currently, there is no effective therapy for this disorder.", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f043e4f36125a426000023", "type": "yesno", "body": "Is Baricitinib effective for Alopecia Areata?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31930807", "http://www.ncbi.nlm.nih.gov/pubmed/34090959", "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "http://www.ncbi.nlm.nih.gov/pubmed/36239359"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31930807", "text": "If indeed these treatments will prove to be effective and safe, they might become the first FDA-approved treatment for alopecia areata.", "offsetInBeginSection": 933, "offsetInEndSection": 1083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34090959", "text": "Logistic regression was used with nonresponder imputation for missing data.", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "text": "INTERPRETATION\nBaricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "text": "CONCLUSION\nWhen compared to placebo, baricitinib is an effective and well-tolerated medication for the treatment of AA.", "offsetInBeginSection": 1237, "offsetInEndSection": 1387, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64137616201352f04a000041", "type": "yesno", "body": "Anemia is not associated with chronic kidney failure", "documents": [], "snippets": []}, {"id": "6415bc8d690f196b5100000f", "type": "factoid", "body": "What is the estimated reduction in time when using online genetic counseling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30121717"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30121717", "text": "y from a high school course (37.3%), college course (28.1%), or online (11.5%). Familiarity was associated with factors such as female gender (p\u2009=\u20090.0", "offsetInBeginSection": 658, "offsetInEndSection": 808, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64163660690f196b5100001d", "type": "yesno", "body": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34440496", "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "http://www.ncbi.nlm.nih.gov/pubmed/35381069"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34440496", "text": "In contrast, individuals with DMD undergoing pharmacotherapies with Deflazacort achieved lower HRV, akin to individuals with DMD without any medications, as demonstrated in the metrics: RMSSD; LF (n.u.", "offsetInBeginSection": 978, "offsetInEndSection": 1128, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "text": "Deflazacort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone.", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "text": "CONCLUSIONS\nThis analysis, limited by its post hoc nature, suggests greater preservation of 6MWD and 4-stair climb with deflazacort vs. prednisone/prednisolone.", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "ndpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differen", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "text": "Further, the drug appears have less negative impact on growth rate in children with diseases requiring corticosteroid therapy.", "offsetInBeginSection": 1192, "offsetInEndSection": 1342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "text": "Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy.", "offsetInBeginSection": 99, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "text": "t corticosteroids be offered (prednisone 0.75 mg/kg/d and deflazacort 0.9 mg/kg/d) as treatment. Recent reports emphasize that longer term treatment w", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "text": "The most common adverse events were abnormal behavior (22 [34%] in the daily prednisone group, 25 [38%] in the daily deflazacort group, and 24 [36%] in the intermittent prednisone group), upper respiratory tract infection (24 [37%], 19 [29%], and 24 [36%], respectively), and vomiting (19 [29%], 17 [26%], and 15 [23%]).", "offsetInBeginSection": 1497, "offsetInEndSection": 1647, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6402bc2d201352f04a000005", "type": "list", "body": "What are the targets of Mosunetuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34914545", "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "http://www.ncbi.nlm.nih.gov/pubmed/17848073"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "CONCLUSION\nMosunetuzumab, administered with step-up dosing, has a manageable safety profile and induces durable complete responses in R/R B-NHL.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": "d blinatumomab), including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor. The model was developed and validated usi", "offsetInBeginSection": 530, "offsetInEndSection": 680, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "text": "Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies.", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "text": "The results were compared with the effect on life expectancy at birth of policies to reduce adult mortality in different ways.", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "Targets are broadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis.", "offsetInBeginSection": 645, "offsetInEndSection": 795, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "RESULTS\nTwo hundred thirty patients were enrolled.", "offsetInBeginSection": 662, "offsetInEndSection": 812, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": "Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma.", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "ging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and ac", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "text": "In both, innate and adaptive immunities are involved, providing a series of potential targets for therapy.", "offsetInBeginSection": 450, "offsetInEndSection": 600, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "text": "With the possible exception of extensive human vaccination, each of these approaches target post-spillover events and none of these avenues of research will have the slightest impact on reducing the risk of additional emergence of viruses or other pathogens from wildlife.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144200201352f04a000043", "type": "yesno", "body": "Is anaphylaxis a results of mast cell activation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27906487", "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "http://www.ncbi.nlm.nih.gov/pubmed/32709306"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "text": "Mouse models of anaphylaxis demonstrate the critical involvement of neutrophils.", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "text": "RECENT FINDINGS\nDrugs are elicitors of anaphylaxis in patients with mastocytosis.", "offsetInBeginSection": 77, "offsetInEndSection": 227, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "text": "The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system activation, and bradykinin formation.", "offsetInBeginSection": 1253, "offsetInEndSection": 1403, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "text": "Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in different mast cell models, and the open questions in the field which remain to be answered.", "offsetInBeginSection": 1017, "offsetInEndSection": 1167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "text": "However, the regulatory mechanism of mast cell activation is not completely understood.", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "text": "Anaphylaxis results from the massive activation of the mast cells (MCs).", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "Recently, we reported that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK).", "offsetInBeginSection": 342, "offsetInEndSection": 492, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "text": "Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence of PK-treatment.", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "text": "CONCLUSIONS\nThese results indicate that neither MBL nor activation of the complement cascade is crucial for the induction of anaphylaxis.", "offsetInBeginSection": 1227, "offsetInEndSection": 1377, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32709306", "text": "CONCLUSIONS\nOur study suggests that the mast cell activation test can be used to diagnose IgE/Fc\u03b5RI-dependent immediate drug hypersensitivity reactions.", "offsetInBeginSection": 1495, "offsetInEndSection": 1645, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c6b6690f196b51000015", "type": "list", "body": "On which two clinical trials was the approval of Keytruda based?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32272501", "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "http://www.ncbi.nlm.nih.gov/pubmed/28235882"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "text": " Merkel cell carcinoma (MCC). Approval was based on Cancer Immunotherapy Trials Network protocol 9, also known as KEYNOTE-017 (NCT02267603), a multice", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "ificant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\u2009<\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing c", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "text": "Approval was based on demonstration of objective tumor responses with prolonged response durations in 89 patients enrolled in a randomized, multicenter, open-label, dose-finding, and activity-estimating phase 1 trial.", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e34690f196b51000021", "type": "yesno", "body": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "http://www.ncbi.nlm.nih.gov/pubmed/30544588"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "In addition, we showed that Duchenne muscular dystrophy patient myocardium exhibited increased TRPC6, m-calpain, and calpain cleavage products compared with control human myocardium.", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "80 mg/kg per week: mean [range] 5.9% [1.1-14.4] of normal). Viltolarsen was well tolerated; no treatment-emergent adverse events required dose reducti", "offsetInBeginSection": 1685, "offsetInEndSection": 1835, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "Duchenne muscular dystrophy is a lethal neuromuscular disease that currently has no effective therapy.", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "Duchenne muscular dystrophy is known to be caused by a defective gene of dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable.", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "text": "It can treat approximately 8-10% of the DMD patient population.", "offsetInBeginSection": 786, "offsetInEndSection": 936, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "Conclusions and Relevance\nSystemic treatment of participants with DMD with viltolarsen induced de novo dystrophin production, and clinical improvement of timed function tests was observed.", "offsetInBeginSection": 2378, "offsetInEndSection": 2528, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "text": "OBJECTIVE\nThe novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "Currently, there is no effective therapy for this disorder.", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640410d1201352f04a000012", "type": "summary", "body": "What is Wilkie's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33083170", "http://www.ncbi.nlm.nih.gov/pubmed/28100055", "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "http://www.ncbi.nlm.nih.gov/pubmed/21276386", "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "http://www.ncbi.nlm.nih.gov/pubmed/34401041"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "text": "The exact incidence of the condition remains unknown, and limited case reports are present in the literature.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28100055", "text": "Superior mesenteric artery syndrome, also Wilkie's syndrome, is an uncommon cause of upper intestinal obstruction.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "text": "Wilkie's syndrome (superior mesenteric artery syndrome) is a rare cause of obstruction to the third part of duodenum due to compression between the superior mesenteric artery and the abdominal aorta.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "text": "Superior mesenteric artery syndrome, also known as Wilkie's syndrome, is a rare cause of proximal duodenum obstruction in children.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "text": "Compression of the inferior part of the horizontal duodenum by the superior mesenteric artery may result in high intestinal obstruction with postprandial or positional discomfort, vomiting and weight loss.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "text": "The superior mesenteric artery syndrome--also known as Wilkie's syndrome or as arteriomesenteric obstruction of the duodenum--is a rare condition of upper intestinal obstruction in which the third part of the duodenum is compressed by the overlying, narrow-angled superior mesenteric artery against the posterior structures.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21276386", "text": "Radiological imaging revealed vascular duodenal compression which was relieved by timely surgical intervention.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "text": "Wilkie's syndrome is a rare cause of duodenal obstruction that can easily be missed at clinical practice.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "text": "Wilkie's syndrome is a rare form of intestinal obstruction, which is commonly disregarded.", "offsetInBeginSection": 1520, "offsetInEndSection": 1670, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34401041", "text": "Failure to diagnose this disease can expose patients to serious health risks.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641461bb201352f04a000046", "type": "summary", "body": "What is a PROTAC?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33160761", "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "http://www.ncbi.nlm.nih.gov/pubmed/32164504", "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "http://www.ncbi.nlm.nih.gov/pubmed/36139095"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "text": "Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "text": "Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "text": "PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ability to selectively degrade target proteins.", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "text": "Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer new opportunities to circumvent some of the limitations associated with traditional small-molecule therapeutics.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32164504", "text": "PROTAC (Proteolysis Targeting Chimera) degraders based on protein knockdown technology are now suggested as a novel option for the treatment of various diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "text": "Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "text": "Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36139095", "text": "PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f839201352f04a000032", "type": "yesno", "body": "Can the concept of digital twins be applied in Precision Nutrition?", "documents": [], "snippets": []}, {"id": "63eef6edf36125a42600000d", "type": "summary", "body": "What is the mechanism of action of Teclistamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34388396", "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "http://www.ncbi.nlm.nih.gov/pubmed/35749004"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "INTERPRETATION\nTeclistamab is a novel treatment approach for relapsed or refractory multiple myeloma.", "offsetInBeginSection": 162, "offsetInEndSection": 312, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "The specific and potent activity of teclistamab against BCMA-expressing cells from MM cell lines, patient samples, and MM xenograft models warrant further evaluation of this bispecific antibody for the treatment of MM.", "offsetInBeginSection": 1020, "offsetInEndSection": 1170, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": "BACKGROUND\nTeclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.", "offsetInBeginSection": 50, "offsetInEndSection": 200, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "CONCLUSIONS\nTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.", "offsetInBeginSection": 1934, "offsetInEndSection": 2084, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "BACKGROUND\nTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.", "offsetInBeginSection": 28, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells.", "offsetInBeginSection": 306, "offsetInEndSection": 456, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": "With active doses, exposure was maintained above the mean EC90.", "offsetInBeginSection": 1295, "offsetInEndSection": 1445, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c8309201352f04a000024", "type": "list", "body": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30688121", "http://www.ncbi.nlm.nih.gov/pubmed/36426309", "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "http://www.ncbi.nlm.nih.gov/pubmed/108658", "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "http://www.ncbi.nlm.nih.gov/pubmed/30688121"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "Intrahepatic cholestasis of pregnancy is a diagnosis of exclusion and presents with unexplained pruritus, abnormal liver function tests, and increased serum bile acid levels, particularly in the third trimester of pregnancy.", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36426309", "text": "Blood tests that confirm obstetric cholestasis should alter the course of treatment.", "offsetInBeginSection": 1270, "offsetInEndSection": 1420, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "text": "Liver biopsies showed centrilobular cholestasis with portal and lobular inflammation and eosinophil infiltration.", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "text": "Our purpose is to present our experience with these two methods in the differential diagnosis of intra and extrahepatic causes of cholestasis.", "offsetInBeginSection": 336, "offsetInEndSection": 486, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "Cholestasis blunted but did not obliterate normal sequential elevations in H-ras found in control livers.", "offsetInBeginSection": 1210, "offsetInEndSection": 1360, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "Despite early elevations of total hepatic DNA and RNA values, cholestatic livers demonstrated a significant threefold suppression of expected hepatocyte mitotic indexes 48 and 72 hours after PH, compared with livers after PH alone.", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/108658", "text": "Hepatic microscopy was abnormal in 12 of 14 infants examined.", "offsetInBeginSection": 422, "offsetInEndSection": 572, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "text": "Common presenting features include fatigue, pruritus, and cholestatic liver enzyme abnormalities wherein elevations of serum alkaline phosphatase and gamma-glutamyltransferases levels exceed those of alanine and aspartate aminotransferases.", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "Serum YKL-40 levels were measured in both groups and correlation analysis were performed between the YKL-40 and other liver function tests.", "offsetInBeginSection": 507, "offsetInEndSection": 657, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c599690f196b51000013", "type": "factoid", "body": "Which company produces Keytruda?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30547369", "http://www.ncbi.nlm.nih.gov/pubmed/26631501"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30547369", "text": "As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda\u00ae) to submit evidence of its clinical and cost effectiveness for the treatment of locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.", "offsetInBeginSection": 79, "offsetInEndSection": 229, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26631501", "text": "lopment of checkpoint inhibitors that target the PD-1/PD-L1 pathway. Pembrolizumab (MK-3475, lambrolizumab, Keytruda(\u00ae)) is a PD-1 inhibitor that has ", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040edf201352f04a000011", "type": "yesno", "body": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34146512", "http://www.ncbi.nlm.nih.gov/pubmed/35841241"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "text": "INTERPRETATION\nPioglitazone did not delay the onset of mild cognitive impairment.", "offsetInBeginSection": 3689, "offsetInEndSection": 3839, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "text": "Power analyses showed that using prognostic models to recruit enriched cohorts of predicted decliners can reduce clinical trial sample sizes by as much as 51% while maintaining the same detection power.", "offsetInBeginSection": 2140, "offsetInEndSection": 2290, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414638c201352f04a000047", "type": "factoid", "body": "Cereblon (CRBN)  has been identified as the target for what type of drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34033753", "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "http://www.ncbi.nlm.nih.gov/pubmed/22966948", "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "http://www.ncbi.nlm.nih.gov/pubmed/25016816"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34033753", "text": "ted with intellectual disability, was identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is a substrate receptor o", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "We had previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase complex, Cullin-Ring ligase 4 (CRL4CRBN) in zebrafish and chicks.", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966948", "text": "A landmark study recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity.", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "text": "Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "text": "Importantly, Aiolos could serve as a proximal pharmacodynamic marker for lenalidomide and pomalidomide, as healthy human subjects administered lenalidomide demonstrated Aiolos degradation in their peripheral T cells.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ", "offsetInBeginSection": 163, "offsetInEndSection": 313, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "These studies raise the possibility that CRBN-based small-molecule compounds regulating the proliferation of neural stem cells may be developed for application in regenerative medicine.", "offsetInBeginSection": 1622, "offsetInEndSection": 1772, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "text": "tly being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by anal", "offsetInBeginSection": 744, "offsetInEndSection": 894, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "text": "BN), has been identified as a direct molecular target for anti-neoplastic activities of IMiDs. CRBN has also been shown to be involved in IMiDs-mediat", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cdb033942b094c000012", "type": "yesno", "body": "Does silencing of SRRM4 promote microexon inclusion?", "documents": [], "snippets": []}, {"id": "63f03a20f36125a42600001c", "type": "list", "body": "Which drugs are included in the AZD7442?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36443846", "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "http://www.ncbi.nlm.nih.gov/pubmed/33532768", "http://www.ncbi.nlm.nih.gov/pubmed/35076282"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36443846", "text": "Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection.", "offsetInBeginSection": 251, "offsetInEndSection": 401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2184, "offsetInEndSection": 2334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "BACKGROUND\nThe monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models.", "offsetInBeginSection": 8, "offsetInEndSection": 158, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "text": "Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.", "offsetInBeginSection": 1, "offsetInEndSection": 151, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2176, "offsetInEndSection": 2326, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "text": "BACKGROUND\nWe report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "text": "BACKGROUND\nIntramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "text": "In total, compared to BA.1, the activity of the Evusheld/AZD7442 is significantly improved against BA.2 while\u00a0BA.5 is intermediate but closer to BA.2.", "offsetInBeginSection": 681, "offsetInEndSection": 831, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33532768", "text": "To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2.", "offsetInBeginSection": 236, "offsetInEndSection": 386, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "text": "Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640ddd9d201352f04a000028", "type": "list", "body": "What were the first 2 PD-1 inhibitors approved by the FDA in 2014?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29357948", "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "http://www.ncbi.nlm.nih.gov/pubmed/34196068", "http://www.ncbi.nlm.nih.gov/pubmed/28546286"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "text": "Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.", "offsetInBeginSection": 447, "offsetInEndSection": 597, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "Identifying biomarkers that can predict response to PD-1 inhibitors is critical to maximizing the benefit of these agents.", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "text": "Two agents - dapagliflozin and empagliflozin - were FDA-approved in January and July 2014, respectively.", "offsetInBeginSection": 599, "offsetInEndSection": 749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "text": "In 2014, the US Food and Drug Administration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab.", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34196068", "text": "BACKGROUND\nTo review and summarize all U.S. Food and Drug Administration (FDA) approvals of programmed death (PD)-1 and PD-ligand 1 blocking antibodies (collectively referred to as PD-[L]1 inhibitors) over a 6-year period and corresponding companion/complementary diagnostic assays.", "offsetInBeginSection": 46, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "text": "This brings the total number of checkpoint inhibitors for the disease to five, prompting questions about how best to use them.", "offsetInBeginSection": 40, "offsetInEndSection": 190, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c4cf690f196b51000006", "type": "factoid", "body": "What is the difference between dermatillomania and skin picking disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32106136", "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/28761349", "http://www.ncbi.nlm.nih.gov/pubmed/29298167", "http://www.ncbi.nlm.nih.gov/pubmed/32541332"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32106136", "text": "We discussed possible explanations of skin picking behavior with ATX in the light of the current literature.", "offsetInBeginSection": 209, "offsetInEndSection": 359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "Photographic measurement is a consistent way of assessing skin lesions, but it does not reflect the impact of skin picking disorder on the individual's life.", "offsetInBeginSection": 1690, "offsetInEndSection": 1840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "This compulsive behavior started off with picking the skin around his nail beds and slowly got worse.", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28761349", "text": "omania), is described as recurrent picking of skin, leading to skin lesions and significant distress or functional impairment. ED is listed as one of ", "offsetInBeginSection": 467, "offsetInEndSection": 617, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167", "text": " picking sufficient to damage cutaneous tissue, but with no underlying dermatological disease. The condition appears as an independent diagnosis in th", "offsetInBeginSection": 63, "offsetInEndSection": 213, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32541332", "text": "To our knowledge, this is the first report of skin picking treated with atomoxetine in a patient with ADHD.", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eefa3bf36125a426000012", "type": "factoid", "body": "What causes Japanese Spotted Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33510192", "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "http://www.ncbi.nlm.nih.gov/pubmed/1431380"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33510192", "text": "Japanese spotted fever, a tick-borne disease caused by Rickettsia japonica, was firstly described in southwestern Japan.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "text": "Japanese spotted fever (JSF) is an uncommon but potentially fatal infection transmitted by tick bites.", "offsetInBeginSection": 21, "offsetInEndSection": 171, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "text": "The study was conducted to determine the minimum inhibitory concentrations (MICs) of several antibacterial agents against Rickettsia japonica, which causes Japanese spotted fever.", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "text": "Late diagnoses may result in aggravated cases of Japanese spotted fever, with the possibility of developing ARDS as a complication.", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "text": "We herein present the case of a 28-day-old female with Japanese spotted fever, who is the youngest reported patient so far.", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "text": "Spotted fever group (SFG) rickettsioses, which are transmitted by ticks, were long thought not to exist in Japan.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "text": "Japanese spotted fever (JSF) is a zoonosis transmitted by ticks carrying the pathogen Rickettsia japonica.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "text": "It is frequently caused by tick bites while working in the mountain areas of citrus cultivations.", "offsetInBeginSection": 1944, "offsetInEndSection": 2094, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "text": "In this case, the patient died 3 days after proper diagnosis and treatment was started.", "offsetInBeginSection": 980, "offsetInEndSection": 1130, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1431380", "text": "in skin inspection, so that it was clinically speculated to be caused by ticks. According to out field research, the tick fauna was very rich througho", "offsetInBeginSection": 211, "offsetInEndSection": 361, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640dde93201352f04a000029", "type": "summary", "body": "What is the difference between PD-1 and PD-L1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26552662", "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "http://www.ncbi.nlm.nih.gov/pubmed/31237152"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "While the difference was significant (Z = 3.31, p < 0.001).", "offsetInBeginSection": 1007, "offsetInEndSection": 1157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "text": "Further, we found that there is no statistically significant difference in efficacy between PD-1 and PD-L1 drugs.", "offsetInBeginSection": 1380, "offsetInEndSection": 1530, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "CONCLUSIONS\nAmong selected patients with pretreated advanced cancer, PD-1/PD-L1 inhibitors, compared with conventional treatments (chemotherapy or targeted therapy), were associated with improvement in overall survival (2.83 months) but not progression-free survival.", "offsetInBeginSection": 136, "offsetInEndSection": 286, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "text": "The short-term remission rate and long-term survival rate of PD-L1(+) patients were significantly lower than those of PD-L1(-) patients, while the long-term mortality was statistically significant higher than that of PD-L1(-) patients in ALL and AML patients(P<0.05).", "offsetInBeginSection": 1209, "offsetInEndSection": 1359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "While the difference was significant (Z = 3.31, p < 0.001).", "offsetInBeginSection": 1311, "offsetInEndSection": 1461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "text": "Immunotherapy targeting the PD-1/PD-L1 pathway should be considered in this distinct DLBCL subgroup.", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "text": "Expression of PD-1/PD-L1 is also associated with Hp infection, and so Hp infection may be an important initiating factor.", "offsetInBeginSection": 1067, "offsetInEndSection": 1217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "text": "Future research should permit more patients with CNS metastases to engage in PD-1 or PDL1 blockade therapy and explore the safety of PD-1 or PD-L1 inhibitors in patients with CNS metastases.", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "text": "RESULTS\nThe PD-L1-positive expression was significantly higher in cancer cases compared with benign tissues, whereas no difference in PD-1 positive expression was found.", "offsetInBeginSection": 721, "offsetInEndSection": 871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31237152", "text": "ive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of I", "offsetInBeginSection": 667, "offsetInEndSection": 817, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f8b2201352f04a000033", "type": "summary", "body": "What would be the benefits of using a virtual digital twin in nutrition?", "documents": [], "snippets": []}, {"id": "64040af9201352f04a00000d", "type": "yesno", "body": "Is levosimendan effective for amyotrophic lateral sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22047468", "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "http://www.ncbi.nlm.nih.gov/pubmed/22206942"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22047468", "text": "dly progressive, fatal neurodegenerative disorder for which there is no effective treatment. The diagnosis is dependent on the clinical presentation a", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "text": "Amyotrophic lateral sclerosis, the most common neurodegenerative disease affecting motor neurons, lacks an effective treatment.", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "text": "Despite decades of clinical trials, effective disease-modifying drugs remain scarce.", "offsetInBeginSection": 74, "offsetInEndSection": 224, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "text": "A phase III study to evaluate the longer term effects of oral levosimendan in ALS is ongoing.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "text": "ation of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the trea", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "text": "A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis.", "offsetInBeginSection": 1012, "offsetInEndSection": 1162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "text": "After more than 20 years, clinical applications have considerably expanded across critical care and emergency medicine, and levosimendan is now under investigation in different cardiac settings (eg, septic shock, pulmonary hypertension) and for non-cardiac applications (eg, amyotrophic lateral sclerosis).", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "text": "A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis.", "offsetInBeginSection": 1009, "offsetInEndSection": 1159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "text": "Therefore, autologous mesenchymal stem cells-derived exosomes combined with neurotrophic factors could potentially be an effective interventional medium for amyotrophic lateral sclerosis.", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "text": "There is currently very limited effective pharmacological treatment for amyotrophic lateral sclerosis.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c0f7690f196b51000001", "type": "list", "body": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25011434", "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "http://www.ncbi.nlm.nih.gov/pubmed/7155674", "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "http://www.ncbi.nlm.nih.gov/pubmed/30671162"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "text": "CONCLUSION\nOrnithine transcarbamylase deficiency was genetically heterogeneous in the seven Korean patients with confirmed ornithine transcarbamylase deficiency diagnosis by biochemical findings and/or genetic analysis, together with two novel mutations in the OTC gene.", "offsetInBeginSection": 859, "offsetInEndSection": 1009, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "text": "Recurrent episodes of bizarre behavior were the only clinical symptoms that finally led to the diagnosis of ornithine transcarbamylase deficiency in an 8-year-old boy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "text": "Its clinical manifestations as lethargy, vomites, coma and cerebral edema are the effect of the higher concentration of the ammonia in plasma.", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "text": "The subtle onset and course of ornithine transcarbamylase deficiency emphasises the need for plasma ammonia and amino acid measurements in clinical situations suggesting a disorder of this nature.", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "text": "Clinical manifestations are more severe in hemizygous males than in heterozygous females.", "offsetInBeginSection": 128, "offsetInEndSection": 278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "text": "In pregnancy it has been associated with altered mental status, seizures, coma and death, especially in the postpartum period.", "offsetInBeginSection": 157, "offsetInEndSection": 307, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "text": "Common neurological symptoms at presentation of a hyperammonemia are a decreased level of consciousness, abnormal motor function or seizures.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7155674", "text": "Subsequently there was severe cerebral atrophy.", "offsetInBeginSection": 80, "offsetInEndSection": 230, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "Late-onset presentation of OTC can cause mild to severe symptoms.", "offsetInBeginSection": 97, "offsetInEndSection": 247, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "Late-onset presentation of OTC can cause mild to severe symptoms.", "offsetInBeginSection": 1133, "offsetInEndSection": 1283, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa197c201352f04a000003", "type": "summary", "body": "How does SRSF11 contribute to metastasis potential of colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36394206"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "protein family, the involvement of SRSF11 in colorectal cancer (CRC) is unknown.\n\n\nMETHODS\nThe TCGA dataset and clinical samples were used to assess S", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef60ef36125a42600000c", "type": "factoid", "body": "Olokizumab is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34101570", "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "http://www.ncbi.nlm.nih.gov/pubmed/24670876", "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/36001712"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "OBJECTIVE\nThis study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors.", "offsetInBeginSection": 94, "offsetInEndSection": 244, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "text": "OBJECTIVES\nThe aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibitor therapy.", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "leukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.\n\n\nMETHODS\nIn a 24-week, phase 3, multicenter, placebo- and acti", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "CONCLUSION\nIn the 2 long-term studies, OKZ treatment demonstrated a safety profile expected for IL-6 blocking agents without new safety signals and led to sustained improvements in RA symptoms, physical function, and quality of life.", "offsetInBeginSection": 1916, "offsetInEndSection": 2066, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24670876", "text": "Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease.", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "CONCLUSIONS\nIn patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks.", "offsetInBeginSection": 2359, "offsetInEndSection": 2509, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "AIM\nTo evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.", "offsetInBeginSection": 442, "offsetInEndSection": 592, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "CONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters.", "offsetInBeginSection": 1489, "offsetInEndSection": 1639, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "CONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters.", "offsetInBeginSection": 1481, "offsetInEndSection": 1631, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "other domains) at week 12, with each olokizumab dose tested for superiority to placebo. We also tested the noninferiority of each olokizumab dose to a", "offsetInBeginSection": 772, "offsetInEndSection": 922, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6413730e201352f04a00003f", "type": "summary", "body": "Please summarize the function of Trophinin-associated protein (TROAP)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18554632", "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "http://www.ncbi.nlm.nih.gov/pubmed/30021381"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "RESULTS\nThe presence of trophinin and the trophinin associated proteins bystin and tastin in human sperm was confirmed by immunohistochemistry.", "offsetInBeginSection": 1175, "offsetInEndSection": 1325, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "text": "Trophinin-associated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors.", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "text": "Here, we demonstrated that ectopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony formation in soft agar and orthotopic liver transplantation in nude mice.", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "text": "Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC.", "offsetInBeginSection": 1099, "offsetInEndSection": 1249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "text": "Trophinin-associated protein (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule regulation.", "offsetInBeginSection": 177, "offsetInEndSection": 327, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "text": "Purpose: Trophinin-associated protein (TROAP) is a cytoplasmic protein that plays a significant role in the processes of embryo transplantation and microtubule regulation.", "offsetInBeginSection": 70, "offsetInEndSection": 220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "text": "We found that TROAP expression correlates with patient survival and speculated that it may be involved in PCa progression.", "offsetInBeginSection": 180, "offsetInEndSection": 330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "In this study we tested the effect of GWRQ on human sperm to evaluate whether the peptide enhances human sperm motility.", "offsetInBeginSection": 179, "offsetInEndSection": 329, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "text": "erified that trophinin associated protein (TROAP) was a direct target of miR-519d-3p in CRC cells. Using Oncomine database analysis, TROAP was confirm", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ed73201352f04a00002f", "type": "summary", "body": "How does SRSF11 promote metastasis of colon cancer?", "documents": [], "snippets": []}, {"id": "63f03fc8f36125a426000021", "type": "factoid", "body": "What disease can be treated with Lenacapavir?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34871187", "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "http://www.ncbi.nlm.nih.gov/pubmed/35544387"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "SUMMARY\nOngoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": " conducted in a Phase 1b study of lenacapavir (Study 4072) in people with HIV (PWH).\n\n\nMETHODS\nMutations were inserted in a proviral DNA clone by site", "offsetInBeginSection": 308, "offsetInEndSection": 458, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": "bo-controlled, dose-ranging, randomized study of lenacapavir in untreated PWH. Participants received a single dose of lenacapavir (up to 750 mg) or pl", "offsetInBeginSection": 794, "offsetInEndSection": 944, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "CONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo.", "offsetInBeginSection": 2216, "offsetInEndSection": 2366, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": " its predicted effectiveness for treatment and prevention, regardless of HIV-1 clades. The established conserved regions hence serve as a hallmark for", "offsetInBeginSection": 1256, "offsetInEndSection": 1406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "text": "This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.", "offsetInBeginSection": 546, "offsetInEndSection": 696, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "SUMMARY\nOngoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "CONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641365f6201352f04a00003a", "type": "yesno", "body": "Is Iron deficiency anemia a common complication of chronic kidney disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17804903", "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "http://www.ncbi.nlm.nih.gov/pubmed/29696955"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17804903", "text": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "text": "However, few studies looked at iron treatment in the nondialysis chronic kidney disease population.", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "text": "iron supplementation is the preferred method for CKD patients on dialysis (CKD stage 5D) and either i.v.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "text": "One of the most common complications of CKD is anemia, the frequency and severity of which increase as kidney failure progresses.", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "text": "An often additional existing iron deficiency should be balanced adequately according to the guidelines.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29696955", "text": "Anemia is one of\nthe common feature of chronic kidney\ndisease.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ef9b201352f04a000031", "type": "yesno", "body": "Can modulation of KCNQ1 splicing prevent arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23608591", "http://www.ncbi.nlm.nih.gov/pubmed/23608591"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.", "offsetInBeginSection": 1615, "offsetInEndSection": 1765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "The consequences of drug-induced KCNQ1 splice alteration remain unknown.", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f57f7f33942b094c000006", "type": "summary", "body": "What is Catamenial pneumothorax?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28925275", "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "http://www.ncbi.nlm.nih.gov/pubmed/27516783", "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "http://www.ncbi.nlm.nih.gov/pubmed/17540999"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28925275", "text": "CONCLUSION\nCatamenial pneumothorax is usually connected with thoracic endometriosis and also includes catamenial hemothorax, recurrent catamenial hemoptysis, catamenial pleural pain as well as endometriosis lung nodules.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "text": "Catamenial pneumothorax is one of the forms of spontaneous pneumothorax.", "offsetInBeginSection": 78, "offsetInEndSection": 228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "text": "The patient was referred to our institution for further evaluation.", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "text": "Catamenial pneumothorax, a variant of spontaneous pneumothorax occurs exclusively in women of menstrual age.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "Since catamenial pneumothorax is caused by thoracic endometriosis, decisions on treatment should be made with a gynecologist's opinion.", "offsetInBeginSection": 1070, "offsetInEndSection": 1220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "text": "It is important to maintain a high index of suspicion of catamenial pneumothorax in patients with a history of endometriosis.", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "Since catamenial pneumothorax is caused by thoracic endometriosis, decisions on treatment should be made with a gynecologist's opinion.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27516783", "text": "The sine qua non criterion is the occurrence of the pneumothorax in the period of 72 hours before or after the menses.", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "text": "We report a case of a catamenial pneumothorax successfully treated with a Gn-RH analogue supporting the efficacy of this regimen and the endometriosis theory as an underlying cause of the disease.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17540999", "text": "Catamenial pneumothorax is a recurrent pneumothorax temporally associated with menstruation.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144419201352f04a000045", "type": "summary", "body": "Please summarize haptenization.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15237856"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "text": "he innate immune system, or haptenization eliciting an immunoallergic response of the adaptive immune system. Besides licensed drugs, herbal and natur", "offsetInBeginSection": 813, "offsetInEndSection": 963, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c124690f196b51000002", "type": "yesno", "body": "Is trichotillomania encountered with equali frequency in males and females?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23116460", "http://www.ncbi.nlm.nih.gov/pubmed/10216392", "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "http://www.ncbi.nlm.nih.gov/pubmed/11286115", "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "http://www.ncbi.nlm.nih.gov/pubmed/30440191"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "text": "Among these students, 19 (9.0%) were engaged in dermatillomania, 28 (13.3%) in trichotillomania and 13 (6.2%) in onychophagia.", "offsetInBeginSection": 1149, "offsetInEndSection": 1299, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10216392", "text": "Its onset is usually in childhood and females are more affected than males.", "offsetInBeginSection": 277, "offsetInEndSection": 427, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": "METHOD\nWe examined the clinical correlates of trichophagia in 68 subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, trichotillomania (85.3% females; mean age, 35.0 +/- 12.5).", "offsetInBeginSection": 297, "offsetInEndSection": 447, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "text": "ified as an obsessive-compulsive spectrum disorder and is seen predominantly in females. This is a non-systematic review article focusing on the psych", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "text": "The role of sex hormones, however, has received little research.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "text": "Trichotillomania is a relatively common disorder; however, not all dermatologists are sufficiently prepared to treat it.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": "CONCLUSIONS\nThese preliminary results suggest that trichophagia is not uncommon in individuals with trichophagia.", "offsetInBeginSection": 1397, "offsetInEndSection": 1547, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11286115", "text": "The mean age of onset is 8 years for males and 12 for females.", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "text": "Given the relatively low response rate, however, a controlled trial is needed before this agent can be said to be more effective than placebo.", "offsetInBeginSection": 887, "offsetInEndSection": 1037, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30440191", "text": "Trichotillomania is a relatively uncommon condition that classically occurs in young females.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64041701201352f04a000017", "type": "list", "body": "What is the triad of the Eagle-Barrett Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35429431", "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "http://www.ncbi.nlm.nih.gov/pubmed/142096", "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "http://www.ncbi.nlm.nih.gov/pubmed/24833922"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "text": "Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "text": "Eagle Barrett syndrome (EBS) is characterized by the triad of abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "text": "Prune Belly syndrome (PBS) or Eagle-Barrett syndrome is an anatomo-radiological syndrome consisting of a complex and rare malformation characterized by the following triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism.", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/142096", "text": "This is a case report of the ultrasonic detection of an enlarged urinary bladder in a 20 1/2 week fetus which subsequently was proven to have the prune belly or Eagle-Barrett syndrome.", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "text": "Clinical and pathologic experience with seven cases of prune-belly syndrome is reviewed.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "text": "The Female Athlete Triad (Triad) represents a syndrome of three interrelated conditions that originate from chronically inadequate energy intake to compensate for energy expenditure; this environment results in insufficient stored energy to maintain physiological processes, a condition known as low energy availability.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c85e9201352f04a000026", "type": "factoid", "body": "What cells proliferate in Mantle Cell Lymphoma", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6362835", "http://www.ncbi.nlm.nih.gov/pubmed/9753060", "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "http://www.ncbi.nlm.nih.gov/pubmed/6362835"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "Apparently, the lymphoid cells of MZL home to the mantle zones of secondary follicles, where they surround, proliferate, and eventually obliterate residual benign germinal centers.", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9753060", "text": "The majority of cases show uniform morphological and phenotypic features characterized by a monotonous proliferation of small-to-medium-sized irregular B cells that express CD5 and bright surface immunoglobulin IgM and IgD.", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "text": "The extranodal manifestation, the growth pattern, and the immunophenotype led to the diagnosis of an extranodal marginal zone B-cell non-Hodgkin's lymphoma (NHL).", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "text": "These consisted either of early mantle cell lymphoma with mantle zone growth pattern, or small extranodal accumulations of cyclin D1+ cells, whereas typical mantle cell lymphoma 'in situ' was not detected.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "In all cases, the small lymphoid cells of the mantle zones did not stain.", "offsetInBeginSection": 963, "offsetInEndSection": 1113, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415bb3c690f196b5100000e", "type": "factoid", "body": "What is the estimated cost reduction when using telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/33027215"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "Telegenetics offered them convenience and reduced travel and associated costs.", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "One economic analysis published thus far reported lower costs than in-person care.", "offsetInBeginSection": 351, "offsetInEndSection": 501, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33027215", "text": "RECENT FINDINGS\nImplementation of telegenetics in health systems is still limited, below 10%, somewhat higher for cancer genetic counseling.", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03ae6f36125a42600001d", "type": "factoid", "body": "What is the target of BI 1015550?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35569036", "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "http://www.ncbi.nlm.nih.gov/pubmed/36299369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "gent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. (Funded by Boehringer Ingelheim; 1305-0013 ClinicalTrials.", "offsetInBeginSection": 2035, "offsetInEndSection": 2185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "referential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. Patients were randomly assigned in a 2:1 ratio to receive ", "offsetInBeginSection": 312, "offsetInEndSection": 462, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.", "offsetInBeginSection": 2251, "offsetInEndSection": 2401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "To better understand the antifibrotic potential of BI 1015550 in vivo, its direct effect on human fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) was investigated in vitro.", "offsetInBeginSection": 1443, "offsetInEndSection": 1593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "ics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMethods\nIn the phase I study, 42 subjects were par", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089be7201352f04a000022", "type": "summary", "body": "Please summarize the difference between REMS and RMPs", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31122578"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "text": "The REMS has the necessary measurement properties to be both a predictive and evaluative clinical index to measure prehospital severity of illness; however, no studies have adequately addressed the intra or inter-rater reliability of the score.", "offsetInBeginSection": 1085, "offsetInEndSection": 1235, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd2f33942b094c000011", "type": "yesno", "body": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35841978", "http://www.ncbi.nlm.nih.gov/pubmed/30404949"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841978", "text": "r, its implication in cardiovascular embryogenesis and diseases remains largely unknown. In this review, we summarize previous findings and reveal the", "offsetInBeginSection": 416, "offsetInEndSection": 566, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "However, the functional significance of microexons and their contribution to signaling diversity is poorly understood.", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeaaaf36125a426000004", "type": "factoid", "body": "Beremagene Geperpavec is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35347281"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDE", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64138ce8201352f04a000042", "type": "factoid", "body": "Hairpatches is a single gene mutation associated with what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23301070"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "This mutation is a model for the rare human disorder \"glomerulonephritis with sparse hair and telangiectases\" (OMIM 137940).", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd0b33942b094c000010", "type": "factoid", "body": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34731606"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34731606", "text": "RBFOX2, which has a well-established role in alternative splicing, is linked to heart diseases.", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f56f7533942b094c000002", "type": "factoid", "body": "Which gene is implicated in Canavan disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18978679", "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "http://www.ncbi.nlm.nih.gov/pubmed/28626388", "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "http://www.ncbi.nlm.nih.gov/pubmed/20129749"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "text": "PURPOSE\nCanavan disease, caused by a deficiency of aspartoacylase, is one of the most common cerebral degenerative diseases of infancy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "text": "Canavan disease is a childhood leukodystrophy caused by mutations in the gene for human aspartoacylase ( ASPA), which leads to an abnormal accumulation of the substrate molecule N-acetyl-aspartate (NAA) in the brain.", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "text": "The bovine aspa gene has also been cloned, and its exon/intron organization is identical to that of the human gene.", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "text": "Canavan disease is a neurodegenerative disease with autosomal recessive inheritance.", "offsetInBeginSection": 196, "offsetInEndSection": 346, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28626388", "text": "Canavan disease is caused by mutations in the gene encoding aspartoacylase (ASPA), a deacetylase that catabolizes N-acetylaspartate (NAA).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "text": "Canavan disease is a spongiform leukodystrophy caused by an autosomal recessive mutation in the aspartoacylase gene.", "offsetInBeginSection": 28, "offsetInEndSection": 178, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "text": "Canavan disease (CD) is an autosomal recessive disorder caused by aspartoacylase (ASPA) gene mutations resulting enzyme deficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "text": "In Canavan disease, spongiform encephalopathy of the brain causes progressive mental retardation, motor deficit and death.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "text": "Canavan disease (MIM 271900) is a rare autosomal recessive leukodystrophy due to mutations in the ASPA gene (MIM 608034) and characterized by a clinical onset at 3-5\u00a0months of life, macrocephaly and poor head control, weak cry and suck, development regression and hypotonia.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20129749", "text": "We report two novel mutations: c.2T>C/M1T, an initiation codon mutation, and c.209A>G/N70S, which is located at the enzyme-substrate binding site.", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6411b4a8201352f04a000035", "type": "yesno", "body": "Is prosopagnosia also known as lack of auditory recognition?", "documents": [], "snippets": []}, {"id": "6415babe690f196b5100000d", "type": "summary", "body": "What is telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34265143", "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/30559758"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "text": "At the University of Pennsylvania (UPenn), a large academic hospital in an urban setting, nearly all genetic counseling (GC) visits for adult-onset disorders within the Department of Neurology were conducted via secure videoconferencing (telegenetics) or telephone between March and December 2020.", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "text": "Telemedicine may also be effectively utilized in clinical genetics services\u2014an application that has been termed \u201ctelegenetics.\u201d\n\n\nMETHODS\nA systematic review of the literature was conducted to identify studies of genetic consultations carried out through video conferencing so as to determine whether conclusions can be drawn about the value of telegenetics.", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "text": "Telemedicine may also be effectively utilized in clinical genetics services-an application that has been termed \"telegenetics.\"", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "text": "Telegenetics could be an effective and efficient way of counseling, but its use in Europe is not widely reported, nor is there evidence of international collaboration.", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "text": "Telegenetics is a satisfactory solution for both patient and provider and provides benefits for rural patients despite ethical, legal, and reimbursement considerations.", "offsetInBeginSection": 424, "offsetInEndSection": 574, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "text": "CPGH rapidly implemented telegenetic services to continue providing care to patients.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "text": "Higher numeracy was associated with higher post-counseling knowledge following telephone genetic counseling (p\u2009<\u20090.001), but not usual care (p\u2009=\u20090.450).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "text": "OBJECTIVE\nVideoconferencing for clinical genetics services, or telegenetics, is becoming an increasingly utilized method of delivering genetic counseling to rural areas; however, there has been little qualitative exploration of the practitioner's experience, particularly for hereditary breast/ovarian cancer counseling.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "We showed online genetic counseling to be effective, feasible and cost-efficient, but technical improvements are needed to increase counselors' satisfaction.", "offsetInBeginSection": 204, "offsetInEndSection": 354, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "The risks associated with the implementation of telegenetics were rarely mentioned.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f04546f36125a426000024", "type": "summary", "body": "What is the mechanism of action of Mitapivat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35964609", "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "http://www.ncbi.nlm.nih.gov/pubmed/36124781"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "text": "INTERPRETATION\nThese efficacy and safety results support the continued investigation of mitapivat for the treatment of both \u03b1-thalassaemia and \u03b2-thalassaemia.", "offsetInBeginSection": 303, "offsetInEndSection": 453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD.", "offsetInBeginSection": 1558, "offsetInEndSection": 1708, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": "The primary endpoint was a reduction in transfusion burden (\u226533% reduction in number of RBC units transfused during the fixed-dose period, compared with the participant's individual historical transfusion burden, standardised to 24 weeks).", "offsetInBeginSection": 818, "offsetInEndSection": 968, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "These data suggest that, even though Townes HbSS mice have increased PKR activity, further activation of PKR with mitapivat yields potentially beneficial effects that are independent of changes in sickling or hemoglobin levels.", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "thophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine tripho", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "These factors can be modulated by mitapivat, which activates erythrocyte pyruvate kinase (PKR) and improves sickling kinetics in SCD patients.", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "METHODS\nIn this uncontrolled, phase 2 study, we evaluated the safety and efficacy of mitapivat in 52 adults with pyruvate kinase deficiency who were not receiving red-cell transfusions.", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "EXPERT OPINION\nMitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD.", "offsetInBeginSection": 755, "offsetInEndSection": 905, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641357bc201352f04a000039", "type": "yesno", "body": "Do cells undergoing necroptosis show disruption of their cell membranes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35293986", "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "http://www.ncbi.nlm.nih.gov/pubmed/35365636"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35293986", "text": "Necroptosis is triggered by death receptors, toll-like receptors, and some viral infections.", "offsetInBeginSection": 663, "offsetInEndSection": 813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "Interestingly, knockdown of Hsp70 in cells leads to MLKL destabilization, suggesting that MLKL might also be a client protein of Hsp70.", "offsetInBeginSection": 1146, "offsetInEndSection": 1296, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "text": "Oligomerization-induced MLKL ubiquitylation occurs on at least four separate lysine residues and correlates with its proteasome- and lysosome-dependent turnover.", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "text": "oss for species adaptation and suggests that necroptosis is not required for normal mammalian development. Moreover, this study highlights a co-evolut", "offsetInBeginSection": 1534, "offsetInEndSection": 1684, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "text": "Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.", "offsetInBeginSection": 664, "offsetInEndSection": 814, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "text": "m MLKL-mediated disruption of the cell membrane. In this issue of Cell, Gong et\u00a0al. challenge the notion that MLKL activation is a point of no return ", "offsetInBeginSection": 83, "offsetInEndSection": 233, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "text": "Finally, based on current evidence, we discuss the potential mechanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "neage kinase domain-like protein (MLKL), which mediate proinflammatory cell membrane disruption. We screened compound libraries provided by the Nation", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "text": "zation and membrane translocation, leading to membrane disruption and a loss of cellular ion homeostasis. It has recently been reported that influenza", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "text": "Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome.", "offsetInBeginSection": 53, "offsetInEndSection": 203, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c3f3690f196b51000005", "type": "summary", "body": "What is the definition of dermatillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "http://www.ncbi.nlm.nih.gov/pubmed/25307926"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "CONCLUSION\nThe comorbidity of factitious disorder and dermatillomania makes diagnosis very difficult.", "offsetInBeginSection": 538, "offsetInEndSection": 688, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "This compulsive behavior started off with picking the skin around his nail beds and slowly got worse.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "text": "Genital dermatillomania has not yet been recognized as a separate entity within the disease.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "text": "Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "text": "A dermatillomania or compulsive skin picking episode may be a conscious response to anxiety or depression but is frequently done as an unconscious habit.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeb70f36125a426000005", "type": "factoid", "body": "What disease can be treated with Glofitamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34953862", "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "http://www.ncbi.nlm.nih.gov/pubmed/33739857"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "text": "This is a novel PKPD-based approach for selection of FIH starting dose for a CD20xCD3 bispecific antibody in B-cell lymphoma, evidenced in the glofitamab study, NP30179 (NCT03075696).", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "text": "Glofitamab appears to be a welcome addition to the treatment possibilities for patients with B-cell lymphomas who otherwise have limited therapeutic options.", "offsetInBeginSection": 809, "offsetInEndSection": 959, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "text": "We review the literature and investigate possible mechanisms involved in the observed responses after administration of glofitamab, such as proliferation of CAR T cells, anti-tumor effects of the bispecific antibody and the role of other possibly contributing factors.", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.", "offsetInBeginSection": 1125, "offsetInEndSection": 1275, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "text": "30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell ", "offsetInBeginSection": 110, "offsetInEndSection": 260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).", "offsetInBeginSection": 174, "offsetInEndSection": 324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "CONCLUSION\nIn patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies.", "offsetInBeginSection": 839, "offsetInEndSection": 989, "beginSection": ["abstract"], "endSection": "abstract"}]}]}